IFNA1 and Cirrhosis: NASVAC, a vaccine formulation containing both hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg), targeted a lower proportion of patients who developed cirrhosis in phase III clinical trials compared with PEG-IFN (144).